Conclusiones
•
FDA/EMA approval: Pembrolizumab 1L NSCLC (both histologies)
PD-L1 >= 50% with an increased OS, PFS, ORR benefit and better
toxicity profile (QoL) than standard CT
•
Preliminary combination (with CT/CTLA-4 inhibitors) strategies
increased % population benefit in terms of PFS/ORR, no OS
benefit and worse toxicity profile
- Closed/Ongoing Phase III results to confirm. New combos?
- Sequence and duration of treatment required (costs!!)
•
Future approach?: PD-L1 >= 50%: Mono-Inmunoterapia
PD-L1 1-49%: Doble-Inmunoterapia
PD-L1 -: CT+Inmuno
